Eculizumab

Details

Files

Generic Name:

Eculizumab

Project Status:

Complete

Therapeutic Area:

Hemolytic Uremic Syndrome, Atypical

Manufacturer:

Alexion Pharma Canada

Call for patient/clinician input open:

December 6, 2012

Brand Name:

Soliris

Project Line:

Reimbursement Review

Project Number:

SR0304-000

Call for patient/clinician input closed:

January 28, 2013

NOC Status at Filing:

Pre NOC

Performance Metric:

N/A — Predated performance metrics

Submission Type:

Initial

Indications:

Hemolytic Uremic Syndrome, Atypical

Recommendation Type:

Do not list

Final Recommendation:

July 18, 2013

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Last Updated : January 7, 2013